Prospective data suggest that BRCA2 and co-occurring somatic alterations, including RB1 loss and MYC amplification, define an aggressive subtype of prostate cancer, the therapeutic implications of which are currently not well understood [10]. Here, BRCA2 is linked to Familial prostate cancer.